• On May 20, Myomo’s President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global Partners Annual Healthcare Company Showcase. The fireside chat will begin at 11:20 a.m ET. The registration link for the conference can be found here.
• Chief Financial Officer David Henry will present at Sidoti’s Virtual Micro Cap Conference being held May 20-21, and will be holding one-on-one meetings with investors throughout the conference. The Company’s presentation will be webcast live at 1:45 p.m. ET on May 21.  The registration link for the conference can be found here.

Read more.

The post Myomo Announces Participation in Upcoming Investor Conferences appeared first on Myomo.

Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC (“The Horton Fund”), a significant shareholder in the Company. Mr. Manko founded The Horton Fund in 2013

“We are pleased to welcome Joe to our Board of Directors,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. ” Through The Horton Fund, Joe has long been a steadfast investor and supporter for years. He brings strong capital markets, strategic planning, and corporate governance experience to our Board, with a history of driving shareholder value in growth businesses. We are pleased to add his perspective as we execute on our Success Pillars for 2026 and beyond.” Read more.

The post Myomo Appoints Joseph M. Manko to its Board of Directors appeared first on Myomo.

MyoPro® orders received during the quarter were up 12% year-over-year

Expanded gross margin, lower operating expenses and narrowed net loss

Conference call begins at 4:30pm Eastern time today

BURLINGTON, Mass. (May 7, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026.

“Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient  sources, increasing market access, demonstrating operating leverage and investing in innovation.  With strong progress against each, first quarter revenue and operating results were above our targets.  We are effectively shifting our business toward recurring patient sources, which represented 49% of revenue in the quarter, up from 25% a year ago. Our MyoConnect program is ramping up nicely and enhancing the clinical quality of prospective patients as well.  This resulted in 11% of pipeline adds and 16% of orders generated by direct billing referrals in the quarter, with the added benefit of a sequential decline in cost per pipeline add,” said Paul Gudonis, Myomo’s Chairman and Chief Executive Officer. Read more.

The post Myomo Reports First Quarter 2026 Financial and Operating Results appeared first on Myomo.

Ottobock Care will offer the MyoPro through its clinics across the country, helping individuals with upper extremity impairment caused by stroke, brachial plexus injury, or other neurological conditions regain function and improve quality of life.

“The MyoPro fits well into our strategy to position our O&P clinics as leaders in providing enhanced neuro-robotic solutions to our patient population. Ottobock Care already assists patients with lower limb mobility issues with a variety of orthotic devices, including the C-Brace, a powered knee-ankle-foot-orthosis. With the MyoPro, we are now able to offer a solution to those with arm and hand paralysis,’” said Kevin Heidenreich, Head of Patient Services at Ottobock Care. Read more.

The post Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S. appeared first on Myomo.

Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Read more.

The post Myomo to Report First Quarter 2026 Financial Results on May 7 appeared first on Myomo.

The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a streamlined mobile interface for customizing EMG settings in person or remotely, including gain, threshold, range of motion, and advanced settings. It also gives clinicians visibility into patient usage and device configurations, helping support more proactive follow-up and care management. Read more.

The post Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement appeared first on Myomo.

Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant capital markets initiatives. Read more.

The post Myomo Appoints William J Febbo to its Board of Directors appeared first on Myomo.

The post Myomo and Elevance Health Agree to Contract for Multi-State Network Participation appeared first on Myomo.

42% of fourth quarter revenue from recurring patient sources

 Record 241 authorizations and orders in the quarter

  Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue

Conference call begins today at 4:30pm Eastern time

BURLINGTON, Mass. (March 9, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025.

“We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics (“O&P”) and International sales channels.  We also achieved our strongest quarter of the year for MyoPro authorizations and orders,” said Paul Gudonis, Myomo’s Chairman and Chief Executive Officer.  “We look forward to improved results from our 2026 marketing initiatives as we place greater emphasis on referrals and other recurring patient sources with a lower customer acquisition cost.” Read more.

The post Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results appeared first on Myomo.

The post Myomo to Report Fourth Quarter 2025 Financial Results on March 9 appeared first on Myomo.